Key result
High plasma NLRP3 linked to ~101% higher odds of high TRS-2P risk scores in ACS.
Why the study?
ACS has a high incidence and mortality rate worldwide, and identifying patients at high risk of recurrent adverse cardiac events using plasma NLRP3 inflammasome is needed.
Does plasma NLRP3 inflammasome level predict high TRS-2P risk score in patients with acute coronary syndrome?
Observational
No
Does plasma NLRP3 inflammasome level predict high TRS-2P risk score in patients with acute coronary syndrome?
Odds Ratio: 2.013 (95% CI 1.174–3.452)
Plasma NLRP3 inflammasome levels may serve as an independent biomarker for predicting high secondary prevention risk in patients with acute coronary syndrome.
May refine ACS risk stratification; hypothesis-generating and requires prospective validation before clinical use.
Purpose: Acute coronary syndrome (ACS) has a high incidence and mortality rate worldwide, which has a considerable negative impact on the global economy. This study aimed to identify a group of ACS patients at a high risk of recurrent adverse cardiac events using the plasma NLRP3 inflammasome. Patients and methods: ACS patients admitted to Liaocheng People's Hospital between June 2021 and March 2022 were enrolled in this study. Patients were divided into low (levels < 3.84 ng/mL) and high (levels ≥ 3.84 ng/mL) groups based on the median NLRP3 inflammasome levels. The patients were divided into three groups according to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P): low (scores ≤ 2 points), intermediate (scores = 3 points), and high (score ≥ 4 points) risk. We investigated the relationship between NLRP3 inflammasome and laboratory indicators. Additionally, we examined whether the NLRP3 inflammasome was an independent predictor of high TRS-2P and explored the applicability of the plasma NLRP3 inflammasome for predicting high TRS-2P. Results: Logistic regression analysis revealed that NLRP3 inflammasome was an independent predictor of high TRS-2P (odds ratio [OR]:2.013; 95% confidence interval [CI]: 1.174-3.452). The area under the receiver operating characteristic curve value of the NLRP3 inflammasome was 0.674 (95% CI: 0.611-0.737; P < 0.001). Conclusion: NLRP3 inflammasome levels are an independent predictive factor for high TRS-2P levels, which indicates that the NLRP3 inflammasome may help predict the prognosis of ACS patients.
No takes yet. Share an insight, caveat, or question.
Mo et al. (2022) conducted an observational in Acute coronary syndrome. Plasma NLRP3 inflammasome levels vs. Low NLRP3 inflammasome levels (< 3.84 ng/mL) was evaluated on High TRS-2P (score ≥ 4 points) (OR 2.013, 95% CI 1.174-3.452). High plasma NLRP3 inflammasome levels independently predicted high TRS-2P risk scores in patients with acute coronary syndrome (OR 2.013; 95% CI 1.174-3.452).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: